Used in research and development of targeted cancer therapies, particularly for tumors overexpressing IGF-1R, such as certain types of sarcomas, breast, lung, and prostate cancers. Acts as a blocking antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway, which plays a role in cell proliferation, survival, and metastasis. Robatumumab serves as a reference standard in immunoassays and binding studies to evaluate the performance of other anti-IGF-1R antibodies. Also utilized in preclinical studies to assess receptor internalization, downstream signaling effects, and potential combination therapies with chemotherapeutic agents or other targeted biologics.